<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315909</url>
  </required_header>
  <id_info>
    <org_study_id>IR.MUMS.REC.1398.125</org_study_id>
    <nct_id>NCT04315909</nct_id>
  </id_info>
  <brief_title>The Effect of Platelet-Rich Plasma-Fibrin Glue in Combination With Vitamin E and C for Treatment of Non-healing Diabetic Foot Ulcers</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-group, Clinical Trial to Evaluate the Effect of Platelet-Rich Plasma-Fibrin Glue in Combination With Vitamin E and C for Treatment of Non-healing Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluates the chance of non-healing Diabetic Foot Ulcers repair
      by reducing oxidative stress caused by diabetes by taking vitamin E and C supplements along
      with the use of Platelet-Rich Plasma-Fibrin Glue as an effective treatment for wound healing.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2019</start_date>
  <completion_date type="Anticipated">June 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 23, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Healing rate of the ulcer</measure>
    <time_frame>2 months</time_frame>
    <description>Examination by a vascular surgery physician and documentation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound Size</measure>
    <time_frame>2 months</time_frame>
    <description>Wound size will be measured with ruler for length, width as well as with digital imaging. Wound size will be assessed in digital images taken of the wound.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum ESR at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>Erythrocyte Sedimentation Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hs-CRP at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>high-sensitivity C-Reactive Protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FBS at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>Fasting blood sugar</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>Glycated hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>Serum Triglyceride, Cholesterol, HDL, LDL, VLDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Urea at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>In a quantitative laboratory method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>In a quantitative laboratory method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total bilirubin at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>In a quantitative laboratory method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Uric acid at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>In a quantitative laboratory method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Homocysteine at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>In a quantitative laboratory method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pro-Oxidant Antioxidant Balance at baseline and after the intervention</measure>
    <time_frame>2 months</time_frame>
    <description>The PAB assay is a test to determine the oxidants and antioxidants simultaneously in one single test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <condition>Diabetic Wound</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus vitamin supplements (E (200 IU/ 2day) and C (250 mg/ 2day) ) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with non-healing Diabetic Foot Ulcers treated with PRP-Fibrin-Glue plus placebo for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRP-Fibrin Glue</intervention_name>
    <description>Platelet-Rich Plasma-Fibrin Glue</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Platelet-Rich Plasma-Fibrin Glue</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin E and C</intervention_name>
    <description>Vitamin E and vitamin C</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. DFU is classified as Wagner 1 -2 on the Wagner classification system.

          2. Persons with type 1 or type 2 diabetes with a non-healing ulcer of at least 4 weeks
             duration.

          3. If more than one non-healing wound is present, the largest of the wounds that is
             classified as a Wagner 1- 2.

          4. The index ulcer had to be clinically non-infected.

          5. Ankle Brachial Index (ABI) greater than or equal to 0.7.

          6. HemoglobinA1C (HbA1c) &lt; 12

          7. Index foot ulcer located on the plantar, medial, or lateral aspect of the foot
             (including all toe surfaces).

          8. Wound area (length x width) measurement between 2 cm2 and 20 cm2.

          9. Non-use of drugs that may interfere with wound healing, such as corticosteroids,
             immunosuppressive agents, and cytotoxic agents.

         10. No smoking, alcohol or drug addiction.

         11. Approved, informed, signed consent.

        Exclusion Criteria:

          1. Previous consumption of vitamin E and C supplements.

          2. Index ulcer has exposed tendons, ligaments, muscle, or bone.

          3. Confirmed presence of osteomyelitis, or if osteomyelitis is suspected.

          4. Patients with renal deficiency, hepatic failure, has known immune insufficiency and
             cancer.

          5. Subject is pregnant or plans to become pregnant during the duration of the trial.

          6. Patient's blood vessels are non-compressible for ABI testing.

          7. Patient is known to have a psychological, developmental, physical, emotional
             disorders.

          8. Received systemic corticosteroids or immunosuppressive agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daryoush Hamidi Alamdari, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daryoush Hamidi Alamdari, Ph.D</last_name>
    <phone>+98 51 3882 8574</phone>
    <email>hamidiad@mums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amir Yarahmadi, Ph.D</last_name>
    <phone>+98 51 3882 8574</phone>
    <email>yarahmadiA961@mums.ac.ir</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alavi Hospital</name>
      <address>
        <city>Mashhad</city>
        <state>Razavi Khorasan</state>
        <zip>9137913316</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad-Hadi Saeed Modaghegh, M.D</last_name>
      <email>ModagheghMH@mums.ac.ir</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Daryoush Hamidi Alamdari</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Platelet-Rich Plasma-Fibrin Glue</keyword>
  <keyword>DFU</keyword>
  <keyword>Vitamin E</keyword>
  <keyword>Vitamin C</keyword>
  <keyword>non-healing Diabetic Foot Ulcers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data related to the project after unidentifiable of people will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Access to data are allowed 6 months after the publication of results.</ipd_time_frame>
    <ipd_access_criteria>The investigator's data will be available for university staffs and academic institutions.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

